Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSULET CORPPODD · Entity 3516 | Director | May 23, 2023 | May 24, 2023 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | May 24, 2018 | May 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSULET CORP
Report date May 23, 2023 · Filed May 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,010 |
Reported balance
After 2023-05-23 transaction · row 1
1 source rowRow 1 · 2023-05-23 · Grant · Acquired 843 · Balance 6,010 F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2024 and are settled in shares of common stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2024 and are settled in shares of common stock on a one-for-one basis.
NEUROCRINE BIOSCIENCES INC
Report date May 24, 2018 · Filed May 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $94.64 · Expires 2028-05-24 | Direct | 12,500 |
Reported balance
After 2018-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-24 · Grant · Acquired 12,500 · Balance 12,500 F1: Option vests in 12 equal monthly installments beginning June 24, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests in 12 equal monthly installments beginning June 24, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2023 Filed May 24, 2023 20:13 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 843 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016716 · form4.xml · nonDerivative · entry 1 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,010 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2024 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:11 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015766 · form4.xml · nonDerivative · entry 1 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,167 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2023 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| May 27, 2021 Filed May 28, 2021 20:11 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 808 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-018312 · form4.xml · nonDerivative · entry 1 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,158 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2022 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:06 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 933 | $231.42 | $215,914.86 |
DisclosureSEC source: 0001127602-21-016804 · form4.xml · nonDerivative · entry 1 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,350 F1 · price: The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $231.20 to $231.43. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:03 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-018254 · form4.xml · nonDerivative · entry 1 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,283 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2021 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:26 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 863 | $196.82 | $169,855.66 |
DisclosureSEC source: 0001209191-20-026778 · doc4.xml · nonDerivative · entry 2 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,254 F1 · shares: The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan. Read SEC document |
| April 30, 2020 Filed May 4, 2020 20:26 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 796 | $195.54 | $155,649.84 |
DisclosureSEC source: 0001209191-20-026778 · doc4.xml · nonDerivative · entry 1 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,117 F1 · shares: The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 21:47 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-020544 · form4.xml · nonDerivative · entry 1 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,913 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2020 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:13 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 3,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-002869 · form4.xml · nonDerivative · entry 1 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,187 F1 · balance_after: The 3,187 restricted stock units vest as to one-half of the total units on January 25, 2020, one-quarter of the total units on January 25, 2021 and one-quarter of the total units on January 25, 2022 , subject to continued service as a director. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| May 24, 2018 Filed May 25, 2018 23:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 12,500 | $0.00 Strike: $94.64 | $0.00 |
DisclosureSEC source: 0001209191-18-033629 · doc4.xml · derivative · entry 1 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-24 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 24, 2018. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:12 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,000 | $83.13 | $415,625.00 |
DisclosureSEC source: 0001209191-18-028971 · doc4.xml · nonDerivative · entry 1 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,283 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $82.42 to $83.69. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 02, 2018 Filed May 3, 2018 23:53 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $7.05 Strike: $7.05 | $105,750.00 |
DisclosureSEC source: 0001209191-18-027902 · doc4.xml · derivative · entry 3 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2018 Filed May 3, 2018 23:53 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,320 | $80.08 | $105,705.60 |
DisclosureSEC source: 0001209191-18-027902 · doc4.xml · nonDerivative · entry 2 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,283 F1 · price: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2011, which, if unexercised would have expired on May 25, 2018. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the Issuer's 2003 Equity Incentive Plan, as amended. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($7.05) was subtracted from the May 02, 2018 market close price ($80.08), and this net amount ($73.03) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,680 shares to the optionee. The 1,320 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. Read SEC document |
| May 02, 2018 Filed May 3, 2018 23:53 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $7.05 | $105,750.00 |
DisclosureSEC source: 0001209191-18-027902 · doc4.xml · nonDerivative · entry 1 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2011, which, if unexercised would have expired on May 25, 2018. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the Issuer's 2003 Equity Incentive Plan, as amended. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($7.05) was subtracted from the May 02, 2018 market close price ($80.08), and this net amount ($73.03) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,680 shares to the optionee. The 1,320 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. Read SEC document |
| May 22, 2017 Filed Jun 8, 2017 22:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $53.64 | $0.00 |
DisclosureSEC source: 0001209191-17-038632 · doc4.xml · derivative · entry 1 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-22 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2017. Read SEC document |
| May 05, 2017 Filed May 9, 2017 00:22 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,000 | $53.98 | $269,900.00 |
DisclosureSEC source: 0001209191-17-030722 · doc4.xml · nonDerivative · entry 1 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,603 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $53.55 to $54.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 03, 2017 Filed May 5, 2017 17:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001209191-17-030238 · doc4.xml · derivative · entry 3 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2017-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2017 Filed May 5, 2017 17:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 952 | $53.37 | $50,808.24 |
DisclosureSEC source: 0001209191-17-030238 · doc4.xml · nonDerivative · entry 2 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,603 F1 · price: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the May 03, 2017 market close price ($53.57), and this net amount ($50.17) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 14,048 shares to the optionee. The 952 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. Read SEC document |
| May 03, 2017 Filed May 5, 2017 17:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $3.40 | $51,000.00 |
DisclosureSEC source: 0001209191-17-030238 · doc4.xml · nonDerivative · entry 1 Nevinny Corinne H · CIK 0001182467 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the May 03, 2017 market close price ($53.57), and this net amount ($50.17) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 14,048 shares to the optionee. The 952 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.